Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) major shareholder James C. Czirr sold 21,323 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $3.06, for a total value of $65,248.38. Following the completion of the transaction, the insider now owns […]
HC Wainwright reaffirmed their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $11.00 target price on the stock. Separately, StockNews.com upgraded Galectin Therapeutics from a sell rating to a hold rating in a report on […]
Retirement Guys Formula LLC grew its stake in Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) by 87.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,500 shares of the company’s stock after buying an additional 10,000 shares during the quarter. Retirement Guys Formula LLC’s […]
Retirement Guys Formula LLC grew its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) by 87.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,500 shares of the company’s stock after buying an additional 10,000 shares […]